Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023
Pharmaceutical Technology
APRIL 28, 2023
Originally granted approval in its largest market, the US, in 2017, Ozempic has subsequently obtained approval for three distinct dosages, 0.5mg, 1.0mg, and 2.0mg, for the treatment of type 2 diabetes. This represents a significant 83% increase in sales between 2022–2029, demonstrating a compound annual growth rate (CAGR) of 9%.
Let's personalize your content